

BioPorto Diagnostics at ISICEM 2013



BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostics tests and antibodies.

BioPorto Diagnostics will be exhibiting at the 33rd ISICEM in Brussels and will be presenting the The NGAL Test™.

The NGAL Test™ CE IVD is a new rapid NGAL assay for clinical chemistry platforms.* Using only a few drops of plasmaor urine The NGAL Test™ gives you results in just 10 minutes and thus addresses the widespread demand for urgent NGAL determination.

The NGAL Test™ is designed for routine diagnostic use on chemistry analyzers from numerous manufactures such as Roche, Abbott, Siemens, Beckman etc. effectively giving almost any laboratory immediate access to a fast and easy method to measure NGAL.

About BioPorto Diagnostics

BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the NASDAQ OMX Copenhagen stock exchange.

To find out more please **visit BioPorto Diagnostics at ISICEM 2013, stand nr. 1.20** or visit: www.bioporto.com and http://ngal.com/

*For in vitro diagnostic use in the European Union, Canada and Korea only.

Published on: Thu, 14 Mar 2013